Survival & performance
Improved survival and recovery
More treated horses have survived septic synovitis and returned to athletic work than with the current standard of care.
Powered by peptides
Proven through clinical trials
A new class of therapeutics
Advancing BIO-PLY™ and a growing pipeline of biologics for high-impact veterinary conditions.
Meet BIO-PLY™, our flagship platelet-derived therapeutic
A peptide-rich cocktail derived from platelets, manufactured under cGMP and curated for maximal activity across infection, inflammation, and tissue healing.
Antimicrobial
Direct antibacterial activity, even against biofilms, supporting a productive immune response in joint and soft-tissue infections.
Anti-inflammatory & chondroprotective
Reduces pro-inflammatory cytokines on par with corticosteroids while protecting cartilage and restoring synovial homeostasis.
Pro-healing
Stimulates hyaluronic acid and collagen synthesis, accelerating recovery in non-healing wounds, tendons, and ligaments.
For veterinarians
Add BIO-PLY™ to your toolkit for joint sepsis, synovitis, and refractory soft-tissue injuries, with reliable clinical results over a short course of intra-articular treatment.
For horse owners
Give your horse the best chance at recovery. BIO-PLY™ has helped 85% of treated horses return to athletic function, even in cases that didn't respond to other treatments.
Our expertise
Expert-led, horse-first
Our team combines deep expertise in equine medicine with modern trial management to deliver results that matter for horses and the people who care for them.
- Board-certified equine specialists
- FDA and regulatory experience
- Scalable biologics platform
Research & evidence
Built on rigorous science. Proven in real horses.
BIO-PLY is backed by platelet-derived biologic research, controlled manufacturing, FDA-supervised clinical study data, and real-world use in leading equine referral centers.
Robust Science
Developed from deep platelet biology and equine clinical insight, BIO-PLY is designed to address biofilms, inflammation, and cartilage damage.
Reliable Production
Our sterile, cGMP process isolates, lyses, and concentrates platelets to deliver high-potency bioactive peptides with reliable lot-to-lot performance.
Clinical Trial Results
In an FDA-supervised study across 100+ cases of septic synovitis, 19 clinical sites, and 28 investigators, BIO-PLY showed superior outcomes versus standard of care.
Real-World Outcomes
Leading referral centers are integrating BIO-PLY into treatment protocols, with repeat use driven by strong clinical results and zero reported adverse events in trial participants.
FDA-supervised pilot trial
Delivering great results for equine health
Early findings from our multi-site clinical study are encouraging: BIO-PLY™ is showing improved outcomes versus the current standard of care for septic synovitis.
Outcomes
Reduced mortality and morbidity
Treated horses are showing fewer deaths and fewer complications from septic synovitis.
Safety
Encouraging safety profile
No adverse events have been reported to date across the multi-site study.